Business
-
Lee’s Pharmaceutical Holdings subsidiary Nova Pneuma has acquired inhaled drug delivery technology and other assets developed by Alexza Pharmaceuticals, the company said. Alexza merged with Grupo Ferrer in 2016. The deal, which is expected to close… Read more . . .
-
US-based start-up CorriXR Therapeutics has announced a partnership with inhaled drug developer InhaTarget Therapeutics and device developer Merxin Ltd for development of an inhaled gene therapy for the treatment of lung cancer. InhaTarget will use its lipid… Read more . . .
-
Glenmark Pharmaceuticals has launched Nebzmart GFB Smartules (glycopyrronium / formoterol / budesonide) and Glenmark Airz FB Smartules (formoterol / budesonide) ampules for the treatment of COPD in India. According to the company, a clinical trial… Read more . . .
-
Chiesi has held an inauguration ceremony for an expanded manufacturing facility in La Chaussée-Saint-Victor, France where the company will manufacture metered dose inhalers with low global warming potential (LGWP) propellants, the company said. Earlier this… Read more . . .
-
Evoke Pharma, which developed and manufactures Gimoti intranasal metoclopramide, has agreed to be acquired by QOL Medical for $11 per share, the companies said. The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020. Evoke… Read more . . .
-
Ritedose Corporation announced that it licensed an ANDA for tobramycin inhalation solution from Hikma and that the FDA has approved the company to manufacture and distribute the product. The company noted that tobramycin, which is… Read more . . .
-
Padagis has announced a $36 million expansion of its manufacturing facilities in Minneapolis, MN, USA, specifically highlighting the new capacity to manufacture naloxone nasal spray in the US. According to the company, “The additional capabilities… Read more . . .
-
ENA Respiratory has announced the closing of a $22.4 million Series B financing, including a previously announced $5 million investment from the Flu Lab and participation by the Gates Foundation. The proceeds will be used… Read more . . .
-
Viatris announced that it has acquired Aculys Pharma, which in 2022 had acquired development and commercialization rights to Neurelis’s NRL-1 (Valtoco) intranasal diazepam for the treatment of epilepsy in Japan, Australia, and other Asia-Pacific countries. In… Read more . . .
-
German CDMO LTS Lohmann has announced that it will acquire US-based CDMO Renaissance Lakewood, which specializes in injectables and nasal sprays. According to the announcement, Renaissance currently employs approximately 500 employees. LTS currently offers services for… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden